Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Relay Therapeutics, Inc. (RLAY)
|
Add to portfolio |
|
|
|
| Price: |
$31.54
| | Metrics |
| OS: |
122.1
|
M
| |
|
|
| Market cap: |
$3.85
|
B
| |
|
|
|
Net cash:
|
$146
|
M
| |
$1.19
|
per share
|
|
EV:
|
$3.71
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 1.4 | 3.0 | 82.7 | 0.0 | 0.0 |
| Revenue growth | -54.4% | -96.3% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.4 | 3.0 | 82.7 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | | |
| Selling, general and administrative | 300.7 | 367.7 | 138.5 | 84.0 | |
| Research and development | 246.4 | 172.7 | 99.9 | 70.3 | 41.0 |
| General and administrative | | | | | 8.9 |
| EBIT | -299.3 | -241.7 | -55.8 | 0.0 | -49.9 |
| EBIT margin | -21670.9% | -7979.5% | -67.5% | | |
| Pre-tax income | -290.5 | -363.9 | -52.4 | -75.3 | -48.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -290.5 | -363.9 | -52.4 | -75.3 | -48.8 |
| Net margin | -21036.1% | -12012.9% | -63.4% | | |
| |
| Diluted EPS | ($2.59) | ($3.82) | ($1.23) | ($21.82) | ($19.63) |
| Shares outstanding (diluted) | 112.2 | 95.1 | 42.6 | 3.5 | 2.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|